Tumor Biology and Microenvironment Program Themes

Theme 1: To identify molecular, cellular determinants of malignancy (metastasis drivers)

Our investigators study key signaling pathways involved in tumorigenicity, tumor cell phenotypical plasticity, and tumor cell drug response (metastasis operatives).

Theme 1 Accomplishments 

Theme 2: To identify and exploit the underlying mechanisms of tumor metastasis (operatives)

Our investigators study the function and underlying mechanisms such as the extracellular proteolysis/signaling network that enable tumor cells to adapt to and eventually overcome the varying microenvironments.

Theme 2 Accomplishments 

Theme 3: To identify and exploit stromal reactivity and host immunity to tumor progression (host response to metastatic tumors)

Our investigators study the interaction of tumor cells with mesenchyme and innate immune cells. We also identify, evaluate and utilize adaptive cellular and humoral immune responses to develop immunotherapy approaches.

Theme 3 Accomplishments 

The Latest From Karmanos Cancer Institute

News

Catching Lung Cancer Early Could Save Your Life

Lung cancer is the leading cause of cancer-related deaths in the U.S. and the second most common cancer for both men and women, according to the A...

Read More

Karmanos Cancer Institute Reveals New Brand Campaign, Showcasing Cancer Survivors and Local Community Businesses

From the patients served by the Barbara Ann Karmanos Institute to the businesses and organizations that Karmanos patients support, Karmanos has la...

Read More

Have 10 Minutes? Here’s What You Need to Know About Cancer Clinical Trials

Did you know that a cancer clinical trial is a research study that examines new cancer-fighting drugs, surgical methods, diagnostic tests, or meth...

Read More
News

WWJ | ‘Houses with Roofs Caved In’: Karmanos Surgeon Explains Stage 0 Breast Cancer (DCIS)

Listen Now

WWJ | Treatment Plans, Clinical Trials and Second Opinions: Navigating a Breast Cancer Diagnosis

Listen Now

Sunday Edition | Second Opinions, Clinical Trials and Second Opinions in Breast Cancer

Listen Now